ABBVIE
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 252
- Registration Number
- NCT02185014
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
- Conditions
- Chronic Hepatitis C Virus (HCV) Infection Genotype 1
- Interventions
- First Posted Date
- 2014-06-19
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 615
- Registration Number
- NCT02167945
- Locations
- 🇺🇸
St. Josephs Hospital and Med Center /ID# 127800, Phoenix, Arizona, United States
🇺🇸Univ of Colorado Cancer Center /ID# 126568, Aurora, Colorado, United States
🇺🇸Encore Borland-Groover Clinical Research /Id# 127781, Jacksonville, Florida, United States
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 509
- Registration Number
- NCT02163694
- Locations
- 🇺🇸
University of Illinois - Chicago /ID# 127576, Chicago, Illinois, United States
🇺🇸Allegheny General Hospital /ID# 135094, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh MC /ID# 125005, Pittsburgh, Pennsylvania, United States
Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease
- Conditions
- Moderate to Severe Crohn's Disease
- Interventions
- Biological: adalimumab
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT02148718
Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 496
- Registration Number
- NCT02143713
Surveillance of Humira in Korean JIA Patients
- Conditions
- Polyarticular Juvenile Idiopathic Arthritis
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 28
- Registration Number
- NCT02141984
A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: ABT-122Biological: adalimumab
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 222
- Registration Number
- NCT02141997
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 127
- Registration Number
- NCT02141282
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center /ID# 134509, Boston, Massachusetts, United States
🇺🇸University of Utah /ID# 130813, Salt Lake City, Utah, United States
🇺🇸Moores Cancer Center at UC San Diego /ID# 128535, La Jolla, California, United States
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
- Conditions
- Crohn's Disease
- First Posted Date
- 2014-05-05
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1446
- Registration Number
- NCT02130362
- Locations
- 🇺🇸
Massachusetts General Hospital /ID# 141552, Boston, Massachusetts, United States
🇺🇸Rady Children's Hospital San Diego /ID# 140883, San Diego, California, United States
🇬🇷General Hospital of Thessaloniki Gennimatas /Id# 163658, Thessaloniki, Greece
Atrasentan Spermatogenesis and Testicular Function
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT02118714
- Locations
- 🇺🇸
Tulane Univ /ID# 130308, New Orleans, Louisiana, United States
🇺🇸Frank Clark Urology Center /ID# 147794, Santa Monica, California, United States
🇺🇸Southern IL Univ School of Med /ID# 129010, Springfield, Illinois, United States